Our recent studies on rat pituitary tissue suggest that the annexin 1 (ANXA1)-dependent inhibitory actions of glucocorticoids on ACTH secretion are effected via a paracrine mechanism that involves protein kinase C (PKC)-dependent translocation of a serine-phosphorylated species of ANXA1 (Ser-P-ANXA1) to the plasma membrane of the nonsecretory folliculostellate cells. In the present study, we have used a human folliculostellate cell line (PDFS) to explore the signaling mechanisms that cause the translocation of Ser-P-ANXA1 to the membrane together with Western blot analysis and flow cytometry to detect the phosphorylated protein. Exposure of PDFS cells to dexamethasone caused time-dependent increases in the expression of ANXA1 mRNA and protein, which were first detected within 2 h of steroid contact. This genomic response was preceded by the appearance within 30 min of substantially increased amounts of Ser-P-ANXA1 and by translocation of the phosphorylated protein to the cell surface. The prompt membrane translocation of Ser-P-ANXA1 provoked by dexamethasone was inhibited by the glucocorticoid receptor, antagonist, mifepristone, but not by actinomycin D or cycloheximide, which effectively inhibit mRNA and protein synthesis respectively in our preparation. It was also inhibited by a nonselective PKC inhibitor (PKC 9 -31 ), by a selective inhibitor of Ca 2؉ -dependent PKCs (Go 6976) and by annexin 5 (which sequesters PKC in other systems). In addition, blockade of phosphatidylinositiol 3-kinase (wortmannin) or MAPK pathways with PD 98059 or UO 126 (selective for MAPK kinse 1 and 2) prevented the steroid-induced translocation of Ser-P-ANXA1 to the cell surface. These results suggest that glucocorticoids induce rapid serine phosphorylation and membrane translocation of ANXA1 via a novel nongenomic, glucocorticoid receptor-dependent mechanism that requires MAPK, phosphatidylinositiol 3-kinase, and Ca 2؉ -dependent PKC pathways. (Endocrinology 144: 1164 -1174, 2003) 
T HE ANNEXINS are a well-conserved family of structurally related proteins that bind Ca 2ϩ and phospholipids. Members of the family are characterized by a highly homologous core domain of four (or eight in the case of annexin 6) internal repeats of a conserved 70-to 75-aminoacid sequence that extends to the C-terminal and permits Ca 2ϩ and phospholipid binding (1) . The N-terminal domain of each family member is unique in length and sequence and appears to determine the biological specificity of the individual proteins; in several cases (e.g. annexin 1), this domain includes potential sites for phosphorylation, glycosylation, and peptidase action (2) . Annexins are implicated in the regulation of many physiological and pathophysiological functions, including cell growth and differentiation (3), inflammation (4) , and neuroendocrine function (5) . Our work has centered on annexin 1 (ANXA1), which we have shown to play a major role in the manifestation of the acute regulatory actions of glucocorticoids (GCs) in the rodent neuroendocrine system, acting at the levels of both the hypothalamus (6 -8) and the anterior pituitary gland (9 -11) .
ANXA1 (previously known as lipocortin 1) is expressed in abundance in the rat and human neuroendocrine system (12, 13) . Within the anterior pituitary gland, it is localized mainly to the S100-positive folliculostellate (FS) cells (13) (14) (15) , but small amounts are also present in the endocrine cells (13, 15, 16) . As in other tissues (17) , GCs regulate both the expression and the subcellular distribution of ANXA1 in the anterior pituitary gland (7, 9, 10) . Their initial effect is to cause translocation of ANXA1 from the cytoplasm to the outer cell surface where it is retained via a Ca 2ϩ -dependent mechanism (7, 9, 10) . Subsequently, the steroids induce de novo ANXA1 synthesis, an action that appears to serve principally to re-plete the diminished stores of the protein (7) . Binding and functional studies suggest that the GC-induced exportation of ANXA1 from pituitary cells is an important mechanism that enables the protein to gain access to binding sites (putative receptors) on the surface of the endocrine cells and thereby exert paracrine/autocrine regulatory actions on the release of ACTH and other pituitary hormones. In support of this hypothesis, we have identified high-affinity ANXA1 binding sites on the surface of all the main subtypes of endocrine cells in the rat anterior pituitary gland (18) and shown that recombinant ANXA1 (8, 9, 19) and peptides derived from the N-terminal of the protein (20) mimic the acute inhibitory actions of GCs on pituitary hormone release. Further evidence of a role for ANXA1 in mediating these early steroid actions has been derived in vitro from studies using antisense probes directed against ANXA1 mRNA (10, 11) and by the use of neutralizing anti-ANXA1 antisera in vivo and in vitro (8, 9, 11, 19, 21) .
The precise role of the FS cells in the anterior pituitary gland is obscure. However, increasing evidence supports the contention that these stellate, agranular cells exert paracrine actions that influence both the growth and the secretory activity of the endocrine cells (22, 23) . They may also protect the endocrine cells from toxins by acting as scavengers (24) . In many respects, the FS cells resemble neuroglial cells and, indeed, they express two important markers of these cells, S-100 and glial fibrillary acidic protein (GFAP). In addition, they show similarities with the dendritic cells of the immune system and have the capacity to produce IL-6 and other cytokines (25) , particularly in the face of an immune challenge (26) . These and other data have led to suggestions that the FS cells may stem from an immunological lineage (27) ; they may therefore provide an important means of local cross-talk between the host-defense and neuroendocrine systems. Our finding that the FS cells are the principle source of ANXA1 within the anterior pituitary gland has led us to propose that ANXA1 serves as a paracrine mediator of GC action in the pituitary gland and that the FS cells are thus an important locus of GC action in this organ (5, 14, 18) . Several other lines of evidence support this view. Firstly, the FS cells are rich in glucocorticoid receptors (GRs; Ref. 28) . Secondly, on a temporal basis, the GC-induced cellular exportation of ANXA1 in the rodent anterior pituitary gland parallels the onset of the steroid inhibition of ACTH secretion, both emerging within 15 min and reaching a maximum within 2 h (9). Thirdly, drugs that inhibit the cellular exportation of ANXA1 also suppress the acute antisecretory actions of GCs (9, 10, 20) . Fourthly, FS cell ANXA1 is found both in the cytoplasm and in association with the plasma membrane, particularly in the stellate projections that lie in close apposition with the endocrine cells (14) . Finally, immunogold labeling suggests that GC treatment results in a marked increase in ANXA1 expression in the FS cells, most notably at the plasma membrane (29) .
The mechanism by which GCs cause the translocation of ANXA1 from the cytoplasm to the cell membrane of FS cells is unknown. ANXA1 does not have a signal sequence and would therefore be unlikely to enter the endoplasmic reticulum-Golgi complex for vesicular packaging. In accord with this premise, the GC-induced cellular exportation of the protein in rodent pituitary tissue is unaffected by drugs that block the conventional exocytotic pathway (30) . Our early studies (9) provided preliminary evidence that the steroids act via a novel nongenomic mechanism to export ANXA1. Our more recent work has identified a role for protein kinase C (PKC) in this regard and shown that the exported protein is serine-phosphorylated (20) . In line with these findings, data from other systems suggest that nongenomic steroid actions fulfil a pivotal role in physiological processes as they regulate ion channels (31) , second messengers and protein kinases, such as protein kinase A (32), PKC, and MAPKs (33, 34) .
In the present study, we have used the first transformed human FS cell line (PDFS), derived from a gonadotroph adenoma of the pituitary (35) , to examine further the mechanism by which glucocorticoids induce the translocation of annexin 1 to the cell membrane. Our data demonstrate clearly that the steroids induce the prompt appearance of a serinephosphorylated species of ANXA1 (Ser-P-ANXA1) that is exported from the cell. They also reveal that the actions of the steroids are effected via a nongenomic GR-dependent signaling cascade that involves Ca 2ϩ -dependent PKC, phosphatidylinositol 3-kinase (PI3-K), and MAPK and that is antagonized by annexin 5 (ANXA5).
Materials and Methods Drugs
Dexamethasone 21-phosphate disodium salt, testosterone, 17␤-estradiol, and progesterone were purchased from Sigma-Aldrich Corp. (Poole, UK). The inhibitors of PKC (PKC 19 -31 and Gö 6976), MAPK (PD98059), or MAPK kinase (MEK; UO 126) were from Calbiochem (CN Bioscience, Beeston, Nottingham, UK). Mifepristone (RU-486) was synthesized by Roussel Uclaf (Romanville, France). Stock solutions of U0126, Gö 6976, PD98059, and actinomycin D (Sigma-Aldrich Corp.) were prepared by dissolving the drugs in dimethylsulfoxide (SigmaAldrich Corp.). PKC 19 -31 was dissolved initially in 5% acetic acid (1 mg/ml; VWR Int., Poole, UK), whereas cycloheximide (Sigma-Aldrich Corp.) and mifepristone were first dissolved in ethanol (VWR Int.). The drugs were diluted in incubation medium immediately before use; the final concentration of the diluents did not exceed 0.04%. Human recombinant ANXA5 was prepared as described previously (36) . Endotoxin contamination was less than 20 pg/ml as measured by the Limulus amoebocyte chromogenic assay.
Antisera
Primary antisera. Total ANXA1 protein was detected using a polyclonal antiserum (pAb) raised in rabbit against human recombinant ANXA1 1-346 ; this antiserum has been well characterized previously in studies on nonendocrine human tissue and cell lines (37) (38) (39) . Phosphorylated forms of ANXA1 were detected using purified pAbs (HiTrap Protein G affinity column, Amersham Pharmacia Biotech, Buckinghamshire, UK) raised in rabbit against ANXA1 15-31 phosphorylated on either the serine residue at position 27 (anti-ser-P-ANXA1 pAb) or on the tyrosine residue at position 21 (anti-tyr-P-ANXA1 pAb), respectively (Neosystem, Strasbourg, France). Anti-ser-P-ANXA1 pAb was then affinity purified by incubation with the serine phosphorylated ANXA1 protein (27-Ser-P-ANXA1) linked to cyanogen bromide-activated Sepharose 4B (Sigma-Aldrich Corp.). Specificity of the antisera raised against phosphorylated ANXA1 proteins was assured by the findings in Western blot and dot blot analyses that neither antibody cross-reacted with the unphosphorylated protein human recombinant ANXA1 (1 g/lane) at the dilution used (1:1000); furthermore, whereas anti-tyr-P-ANXA1 pAb readily detected ANXA1 Ac2-26 21-Tyr-P, it failed to recognize a peptide in which the 21Tyr residue was replaced with phenylalanine. Conversely, at a dilution of 1:1000, the affinity purified anti-27-Ser-P-ANXA1 pAb showed no cross-reactivity with the tyrosine phosphorylated peptide ANXA1 Ac2-26 21-Tyr-P or an unrelated phosphoserine peptide in a dot blot study but detected 10 ng of the serine phosphorylated peptide against which it was raised. Antisera against human S100 (raised in rabbit), GFAP (monoclonal, clone G-A-5), human vimentin (monoclonal, clone VIM-13.2), and sea urchin ␣-tubulin (monoclonal, clone B-5-1-2) were all purchased from Sigma-Aldrich Corp. A fluorescein isothiocyanate (FITC)-labeled anti-CD14 monoclonal antibody raised against human CD14 (clone M⌽P9, Becton Dickinson, BD Biosciences, Oxford, UK) was also used. For experiments, the cells were plated at a density of 1 million cells/ well in poly-lysine coated (Sigma-Aldrich Corp.) 10-cm cell culture plates (Corning, Ltd., High Wycombe, UK) and incubated in the conditions described above until the cells attained 70% confluence (24 - 
Determination of ANXA1 mRNA by RT-PCR
Expression of mRNA for ANXA1 was analyzed by RT-PCR using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a control. Details of the primers used are shown in Table 1 . Total RNA was extracted from the samples according to the manufacturer's instructions using the RNAeasy QIAGEN Kit (QIAGEN Ltd., Crawley UK). The samples were then analyzed for RNA concentration and purity by spectrophotometry and stored at Ϫ80 C until required. For first-strand cDNA synthesis, 3 g total RNA from each sample was denatured with 3 l oligo (deoxythymidine) 15 primer (Promega Corp., Southampton, UK) for 5 min at 65 C and reverse transcribed by incubation at 42 C for 2 h in a total volume of 40 l buffer comprising 1.25 mm deoxy-NTPs (Amersham Biosciences, Buckinghamshire, UK), 4 U/ml ribonuclease inhibitor (RNAsine; Promega Corp.), and 9 U Moloney murine leukemia virus (Promega Corp.). For the PCR, an equivalent of 50 -100 ng mRNA together with 50 mm MgCl 2 , 10 mm deoxy-NTP, 50 mm KCl, 10 mm Tris-Cl (pH 8.3), 1 l Taq polymerase (5 U/ml), and 0.5 pmol/l of each of the specific primers (Table 1 ) was used in a total volume of 100 l. The cycling parameters consisted of an initial denaturing step at 95 C for 5 min, followed by 30 cycles of denaturation (95 C, 1 min), primer specific annealing (1 min, see Table 1 for temperature) and extension (72 C, 1 min) and a final extension stage (15 min, 72 C). The PCR products (10 l per lane) were separated by electrophoresis [100 V, 30 min in Tris acetate EDTA buffer (Invitrogen)] on 1% agarose gels (Invitrogen) and stained with ethidium bromide (Sigma-Aldrich Corp.). Analysis of the gels was performed under UV light using a camera image analysis system (Herolab GmBH Laborgerte, Wiesloch, Germany) and TINA software (version 2.10, Raytest Isotopenmessgeräte GmBH, Straubenhardt, Germany). Amplification of the correct sequence was confirmed by product length (DNA molecular weight marker III; Roche Molecular Biochemicals, Mannheim, Germany) and also by amplification of ANXA1, control plasmids (39) . Preliminary studies confirmed that the degree of product amplification (ANXA1 and GAPDH) obtained under these assay conditions was within the exponential range of the curve, thereby permitting semiquantitative analysis of mRNA expression by comparison with GAPDH. Experiments were repeated three times.
Western blot analysis
Expression of ANXA1 protein was examined in duplicate by SDS-PAGE. Briefly, total protein was extracted from the cells by freeze and thawing (38) , protein content was estimated according to (40) , and the sample either analyzed immediately or stored at Ϫ80 C. For those experiments in which cell surface and intracellular ANXA1 were measured, the cells were first washed for 10 min on ice with PBS containing protease and phosphatase inhibitors [1 mm phenylmethylsulfonyl fluoride, 1 g/ml leupeptin, 1 g/ml pepstatin, 1g/ml aprotinin, 1 m Na 3 VO 4 , 1 m NaF (all from Sigma-Aldrich Corp.) in 1 mm EDTA (Sigma-Aldrich Corp.), which acts as a Ca 2ϩ chelating agent and removes ANXA1 attached to the cell surface]; the washes were retained for ANXA1 measurement (cell surface ANXA1). For analysis, samples (30 G protein per well) were loaded onto 10% acrylamide gels and separated by SDS-PAGE in denaturing conditions at 50 mA for 90 min. The separated proteins were then transferred electrophoretically (100 mA per blot 70 min; 2117 MULTIFOR II, Pharmacia LKB, Bromma, Sweden) to nitrocellulose paper (Hybond-P Amersham Biosciences) soaked in transfer buffer [25 mm Tris, 192 mm glycine (Sigma-Aldrich Corp.)] and 20% methanol vol/vol (VWR Int.). Nonspecific binding was blocked by incubation of the blots in 5% milk powder (Marvel, Knighton Edbaston, Stafford, UK) in TBS-Tween [50 mm Tris; 150 mm NaCl; and 0.1% Tween vol/vol (all from Sigma-Aldrich Corp.)] for 60 min. After washing, the blots were incubated overnight at 4 C in primary antibody (diluted 1:1000) and then for 1 h at room temperature with the appropriate secondary antibody (diluted 1:25,000). Immunoreactive protein bands were detected by chemiluminescence using enhanced chemiluminescence reagents and exposed to Hyperfilm (both from Amersham Biosciences). The blots were then scanned and analyzed (HP Scanjet 5200 with Adobe Photodeluxe Business Edition, version 1.1; Cupertino, CA).
FACS analysis
Quantification of cell surface ser-P-ANXA1 expression. Aliquots of the cell suspension (1-3 ϫ 10 5 cells in 100 l) were added to a 96-flat well plate in triplicate and incubated at 4 C for 1 h in the presence or absence (controls) of anti-ser-P ANXA1 pAb (1:300) in a buffer A; containing HEPES (25 mm), CaCl 2 (1 mm), and MgCl 2 (1 mm); nonspecific binding was minimized by the addition of human IgG (1.6 mg/ml, Roche Quantification of intracellular ser-P-ANXA1 expression. The protocol was as above except that saponin (0.0025% wt/vol, Sigma-Aldrich Corp.) was included in the medium during the period of contact with both the primary and secondary antibodies so as to permeabilize the cells. Parallels measure of ␣-actin were made to measure the effectiveness of the permeabilization procedure.
Detection of cell marker proteins. Aliquots of PDFS cells were also incubated as described above (in saponin and buffer A) in the presence or absence of antisera against S100 ( 
Statistics
The optical density of bands of ANXA1 gene expression and immunoreactivity (arbitrary units) detected by RT-PCR and Western blot analyses respectively (see Figs. 2 and 3 ) was corrected for loading error by expression as a percentage of house keeping marker (GAPDH or ␣-tubulin). Responses to the steroids were calculated as a percentage of the corresponding drug-free (i.e. basal) control and expressed as mean Ϯ sem (n ϭ 3 gels); statistical comparison between groups were made using the Mann-Whitney U test. It must be noted that these measurements are essentially semiquantitative and give only a relative numerical guide to the ratios of the band intensities and their variance.
The data derived by FACS analysis were normally distributed (Shapiro and Wilkes test) and were analyzed by standard parametric tests, ANOVA with post hoc comparisons by the Bonferroni test. Statistical comparison were made on the mean data from three experiments (i.e. n ϭ 3), each comprising three cell aliquots per experimental group. The data are expressed as mean Ϯ sem. Differences were considered significant if P Ͻ 0.05.
Results

Characterization of the PDFS cells
In initial experiments, we used FACS analysis to examine the expression of three well-defined FS cell markers, S-100, GFAP, and vimentin, by the PDFS cells. Figure 1A shows clearly that the cells were positive for all three markers. As S100 and GFAP are also markers of neuroglial cells, these findings suggest that, like normal FS cells, the PDFS cells show some characteristics of neuroglial cells. Further studies revealed that, like microglia (41), the PDFS cells also express the monocyte/macrophage marker CD14 (Fig. 1B) as too does the murine FS cell line, TtT/GF (26) . Taken together, the data raise the possibility that the PDFS cells are a potential pituitary monocyte/macrophage cell line with glia-like characteristics. Figure 2 shows the time-dependent effects of dexamethasone (1 m) on the expression and serine/tyrosine phosphorylation status of ANXA1 in the PDFS cells, as determined by Western blot analysis. Dexamethasone initiated a marked increase in ANXA1 mRNA ( Fig. 2A) and protein (Fig. 2B) expression. The response emerged within 2 h of steroid contact, was maximal after 8 h (P Ͻ 0.01) and fell thereafter to a nadir at 16 h; an apparent secondary increase in ANXA1 mRNA expression at 24 h did not reach significance. In addition, dexamethasone caused a marked increase in the expression of serine phosphorylated species of ANXA1 (Ser-P-ANXA1) in the cells (Fig. 2C) . Unlike the changes in ANXA1 mRNA and protein provoked by the steroid, the maximal levels of Ser-P-ANXA1 were evident within 30 min of contact with dexamethasone (P Ͻ 0.01) and declined with time over the ensuing 24 h. A tyrosine-phosphorylated spe- cies of ANXA1 was also detectable in the PDFS cells by Western blot analysis; the amount present was, however, only modest and was unaffected by exposure of the cells to dexamethasone (Fig. 2C) . By contrast, none of the other steroids tested (testosterone, 17␤-estradiol, progesterone 1 m, 30 min or 2 h) affected the expression, cellular disposition, or phosphorylation status of ANXA1 (data not shown). Figure 3 illustrates the effects of dexamethasone (1 m) on the distribution of Ser-P-ANXA1 between the cytoplasm (intracellular) and the plasma membrane (cell surface ANXA1) of PDFS cells, as determined by Western blot (Fig. 3A) and FACS (Fig. 3, B and C) analyses. In the absence of steroid, small amounts of Ser-P-ANXA1 were detectable by both methods both within the cells and on the cell membrane. Exposure of the cells to dexamethasone for up to 8 h caused a prompt and persistent increase in cell surface Ser-P-ANXA1, with maximal levels occurring at 30 min (P Ͻ 0. 01  Fig. 3A) ; an increase in intracellular Ser-P-ANXA1 was also observed after 2 h contact with the steroid (P Ͻ 0.05). Similarly, when Ser-P-ANXA1 was measured by FACS analysis after a 30-min exposure to dexamethasone (1 m), substantially increased amounts of the protein were observed on the cell surface (P Ͻ 0.001, Fig. 3 , B and C); in contrast, a decrease in cytoplasmic Ser-P-ANXA1 was evident at this time (P Ͻ 0.05, Fig. 3C ). No changes in the expression or cellular disposition of Ser-P-ANXA1 were detectable with shorter periods of steroid contact (5 min, data not shown). Inclusion of the GR antagonist, mifepristone (1 m), in the medium (30 min before and during the period of steroid contact) prevented the appearance of Ser-P-ANXA1 on the cell surface induced by exposure to dexamethasone for 30 min (P Ͻ 0.005) or 2 h (P Ͻ 0.005), suggesting that these actions of the steroid are mediated via the GR (Fig. 4) . Mifepristone alone had no effect on membrane Ser-P-ANXA1 during the shorter contact time (i.e. 30-min preincubation plus 30-min incubation period). However, when in contact with the cells for a total of 2.5 h (30-min preincubation plus 2-h incubation period), it caused a small but significant increase (P Ͻ 0.005) in membrane Ser-P-ANXA1. This may reflect the partial agonist activity of the drug at the GR [ Fig. 4B, (42) ], although such a mechanism would not explain the powerful combined actions of mifepristone with dexamethasone. Figure 5 illustrates the effects of the mRNA and protein synthesis inhibitors, actinomycin D (Act-D, 10 g/ml) and cycloheximide (CHX, 5 m), on de novo protein synthesis (Fig.  5A ) and on the ability of dexamethasone (1 m, 30 min and 2 h contact times) to cause the translocation of Ser-P-ANXA1 to the cell surface (Fig. 5, B and C) . Dexamethasone (1 m, 2 h) caused a significant increase in de novo protein synthesis as indexed by the incorporation of [
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14 C]-lysine into protein (P Ͻ 0.001). This effect was abolished by actinomycin D and cycloheximide (P Ͻ 0.001), which themselves also reduced the basal rate of protein synthesis (P Ͻ 0.05, Fig. 5A ). The relatively modest (Ϸ50%) inhibitory effect of cycloheximide and actinomycin D on basal protein synthesis reflects the fact that the cells were preloaded with 14 C-lysine before the addition of the mRNA/protein synthesis inhibitors. Neither actinomycin D (Fig. 5B) or cycloheximide (Fig. 5C ) influenced the translocation of Ser-P-ANXA1 to the cell surface, which was evident after a 30-min contact period with dexamethasone, a finding that suggests that this early action of the steroid is effected via a nongenomic mechanism. By contrast, cycloheximide (Fig. 5B) abolished (P Ͻ 0.005) and actinomycin D attenuated ( Fig. 5C ; P Ͻ 0.05) the effects of dexamethasone observed after a 2-h contact period, indicating that a later phase of the response required de novo mRNA/ protein synthesis.
Blockade of the dexamethasone-induced translocation of Ser-P-ANXA1 to the cell surface by inhibitors of PKC, PI3-kinase, and MAPK
To investigate the signal transduction pathways involved in the early nongenomic effects of dexamethasone in PDFS cells, we examined the effects of PKC, PI3-kinase, and MEK inhibitors on the expression of Ser-P-ANXA1 on the cell membrane induced by contact with dexamethasone (1 m, 30 min). A nonselective PKC inhibitor (PKC 19 -31 , 100 nm), which itself had no effect on the cell surface expression of Ser-P-ANXA1 (P Ͼ 0.05), completely abolished the response to the steroid (Fig. 6, A and B , P Ͻ 0.001). A similar inhibitory effect was also observed in cells treated with a selective inhibitor of conventional Ca 2ϩ -dependent PKCs, GÖ 6976 (25 nm, P Ͻ 0.05, Fig. 6B ), or with the PI3-kinase inhibitor wort- mannin (10 nm, Fig. 6C , P Ͻ 0.05). Blockade of MAPK also inhibited the dexamethasone-induced translocation of Ser-P-ANXA1 to the cell membrane of PDFS cells (Fig. 6C) . The effects of the steroid were thus antagonized by an MEK-MAPK inhibitor PD98059 (5 m; P Ͻ 0.005) and by a selective MEK1 and 2 inhibitor (UO126, 1 M; P Ͻ 0.005), which itself also produced a small reduction in cell surface Ser-P-ANXA1. The specificity of the drugs was confirmed by the demonstration that phorbol 12-myristate-13-acetate and dexamethasone induce the expression of phospho-P44 -42 (assessed by Western blot analysis), and their effects are blocked by PD98459 and U0126 (data not shown). Taken together, these data indicate that the nongenomic actions of dexamethasone that provoke the translocation of Ser-P-ANXA1 to the plasma membrane are effected via a signaling pathway that requires PKC and MEK kinases.
As ANXA5 opposes the inhibitory effects of GCs and ANXA1 on the secretion of ACTH and in vitro (20) and inhibits PKC activity in a cell-free system (43), we also examined the effects of ANXA5 on the dexamethasone-induced translocation of Ser-P-ANXA1 to the cell surface. The results show that ANXA5 (30 nm; 30 min preincubation) impaired the response to the steroid (Fig. 7 , A and B, P Ͻ 0.05).
Discussion
The results show clearly that, in addition to promoting de novo ANXA1 mRNA and protein synthesis, GCs exert more immediate effects in PDFS cells, which lead to serine-phosphorylation of ANXA1 and translocation of the newly phosphorylated protein to the cell surface. They also reveal that the latter process is effected via a novel GR-dependent, but nongenomic, mechanism requiring both PKC and MAPK pathways. Interestingly, dexamethasone had no effect on the tyrosine phosphorylation status of ANXA1, a finding that contrasts with recent data on the A549 cell line (human lung carcinoma; Ref. 44 ) and raises the possibility that GCs phosphorylate ANXA1 in a cell-and tissue-specific manner.
In recent years, increasing evidence has accumulated to support the premise that GCs and other steroid hormones exert rapid effects that cannot be accommodated within the classical framework of steroid action, i.e. through alterations in transcription brought about by interactions of the activated ligand-receptor complex with DNA, transcription factors, or coactivators/corepressors (45) . The nongenomic actions, which emerge in minutes rather than hours, as is usually the case for genomic actions, have been most widely studied in neuronal tissues (46) , but there is also substantive evidence for such actions in the endocrine system and elsewhere (29) . With respect to feedback actions of GCs within ANXA1. Note 1) the low background fluorescence due to the second antibody (IIAb) alone and 2) that actin (an intracellular protein) was barely detectable, indicating that the membrane has retained its integrity. PKC 9 -31 alone had no effect on the membrane expression of Ser-P-ANXA1, but it blocked the response to the steroid. B and C, Mean data Ϯ SEM from three experiments [corrected for background fluorescence and calculated as a percentage of the steroid-free control (MIF ϭ 17 Ϯ 0.7 and MIF ϭ 17.9 Ϯ 1, respectively)]; *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001 vs. untreated controls; #, P Ͻ 0.05; ##, P Ͻ 0.01; ###, P Ͻ 0.001; vs. dexamethasone alone (ANOVA and Bonferroni test). the hypothalamo-pituitary-adrenal axis, nongenomic actions have been associated principally with the initial rapid phase of feedback, which is evident within 2-3 min of steroid contact and persists for up to 15 min (47) . As reviewed briefly in the introduction, our work suggests that ANXA1 is concerned with the manifestation of the second phase of GC inhibition within this axis, i.e. the early delayed phase, which emerges within 15-30 min of a steroid challenge and persists for up to 24 h (48), and that its actions in the pituitary gland are mediated via a paracrine mechanism involving translocation of the protein to the surface of FS cells (9 -11) . It has frequently been suggested that the early delayed feedback actions of GCs are effected via classical genomic actions (5) . In accord with this view, the present data demonstrate de novo expression of ANXA1 mRNA and protein in PDFS cells treated for 2 h with dexamethasone. In addition, they show that the concomitant steroid-induced translocation of Ser-P-ANXA1 to the cell membrane observed at this time point is susceptible to inhibition by mifepristone, actinomycin D, and cycloheximide and is thus dependent upon GR-mediated mRNA and protein synthesis. In contrast, however, the cellular exportation of Ser-P-ANXA1 that occurred during a shorter period of steroid contact (30 min) was unaffected by actinomycin D or cycloheximide. These novel findings suggest that in the first instance the steroid-induced exportation of Ser-P-ANXA1 is independent of transcription/translation and is, thus, effected via a nongenomic GR-dependent mechanism. Taken together, these findings raise the possibility that the early-delayed feedback actions of GCs within the hypothalamo-pituitary-adrenal axis involve both genomic and nongenomic mechanisms, as was also mooted by Taylor et al. (9) .
The mechanisms of nongenomic steroid actions are a focus of much current research. Particular attention has focused on the allosteric actions of neurosteroids on membrane-bound neurotransmitter receptors within the brain, for example the GABA A receptor (46, 49) . However, increasing evidence points to the existence of specific membrane-bound steroid receptors (50) , which may be coupled either to PKC-or protein kinase A-dependent signaling pathways via G proteins (51, 52) or to other signaling systems. For example, in MCF-7 cells (mammary gland tumor cells) ligand activation of the estrogen receptor triggers the tysosine-kinase/p21 ras / MAPK pathway (53), whereas 17␤-estradiol activates MAPK pathways in rat cardiomyocytes (33) . Further nongenomic steroid actions leading, for example, to activation of MAPK and other signaling cascades may also be brought about through stimulation of the classical intracellular receptors (54) . Our data show that the early actions of dexamethasone within the PDFS cells, which cause the translocation of serine-phosphorylated ANXA1 to the cell membrane, are blocked by mifepristone. They thus suggest that the actions of the steroid are mediated by GR, although extensive pharmacological studies with more selective compounds are required to verify this. Although we did not examine the effects of mifepristone and other drugs on the intracellular pool of Ser-P-ANXA1, the fact that we could not detect changes in total or membrane Ser-P-ANXA1 with dexamethasone contact times of less than 30 min (data not shown) and that after 30-min exposure to the steroid much of the phosphorylated protein was found in association with the cell membrane suggests that phosphorylation of ANXA1 is an important early step in this GR-dependent, nongenomic signaling cascade. Direct measures of steroid-dependent ANXA1 phosphorylation following exposure to mifepristone and RNA/ protein synthesis inhibitors are now underway to address this issue.
As a first step toward the characterization of the signaling mechanisms effecting the prompt, steroid-induced translocation of Ser-P-ANXA1 to the cell surface in PDFS cells, we explored the potential roles of PKCs and MAPK, both of which have been implicated in nongenomic steroid signaling in other systems (33, 34) . Our findings suggest that both enzyme systems have an essential part to play. With respect to PKC, the results demonstrate that the dexamethasoneinduced translocation of the phosphorylated protein to the cell membrane is effectively blocked by the nonselective PKC A, Representative scan and shows the fluorescence intensity of cells stained for membrane-bound Ser-P-ANXA1. Note that the low background fluorescence due to the second antibody (IIAb) and that, whereas ANXA5 alone had no effect on the membrane expression of Ser-P-ANXA1, it reduced the response to the steroid. B, Mean data Ϯ SEM from three experiments (corrected for background fluorescence and calculated as a percentage of the steroid-free control (MIF ϭ 74.04 Ϯ 2.3). *, P Ͻ 0.05 vs. untreated controls; #, P Ͻ 0.05; vs. dexamethasone alone (ANOVA and Bonferroni test).
inhibitor PKC 19 -36 ; they also provide evidence that the PKC isoform responsible is Ca 2ϩ -dependent and therefore likely to be of the ␣, ␤ 1 , ␤ 11 , or ␥ subtype. These findings accord with our recent findings in rodent pituitary tissue that dexamethasone acts via a PKC-dependent mechanism to induce the cellular exportation of Ser-P-ANXA1 (20) and with data from our own and other groups that suggest that PKC plays an essential role in the manifestation of the early delayed feedback actions of GCs on the pituitary gland (20, 55) . Whether the Ca 2ϩ -dependent PKC itself causes serine-phosphorylation of ANXA1 in the PDFS cells, as it does in other systems (56) , or acts at a different point in the steroid-signaling cascade to facilitate the translocation of the phosphorylated protein to the cell membrane remains to be determined. In addition to identifying a role for PKC, this study also demonstrated that the translocation of Ser-P-ANXA1 to the cell membrane provoked by dexamethasone is inhibited by wortmannin, PD98059 and U0126 and is thus dependent on PI3-kinase, MAPK, and MEK. Data from other systems have provided evidence that PKC can be activated by PI3-kinase, raising the possibility that ANXA1 is serine phosphorylated as a consequence of sequential PI3-kinase-PKC activation. For example, as PKC is activated by PtIns(3,4)P2 and PtIns(3,4,5)P3 (57) (58) (59) and the phosphorylation of the PKC substrate pleckstrin is inhibited by wortmannin (60), Ser-P-ANXA1 could be phosphorylated as a consequence of PI3-K-PKC activation. Further work is now required to investigate this possibility and to explore the role of the MAPK system, which is increasingly being implicated in signaling systems within the pituitary gland (61) .
A further interesting observation reported here is the ability of ANXA5 to suppress the steroid-induced appearance of Ser-P-ANXA1 on the cell surface. How this occurs is unclear but, if a similar phenomenon occurs in primary pituitary tissue, it may go some way to explain our recent finding that ANXA5 opposes the inhibitory effects of dexamethasone on the secretion of ACTH and other pituitary hormones (20) . In a previous study (18), we described specific ANXA5 binding sites on the surface of rat pituitary cells that might serve either as receptors, and therefore be coupled to a signaling system, or to transport the protein across the cell membrane. Interestingly, in a number of cell-free systems, ANXA5 has been shown to inhibit the PKC-dependent substrate phosphorylation (43, 56, 62) via a mechanism that involves direct inhibition of the kinase (63), rather than phosphorylation of ANXA5 as an alternative substrate (64) . Certainly in the light of the data reported here, if ANXA5 enters the cells, blockade of PKC would provide an effective means of opposing the regulatory actions of the steroids on the translocation of Ser-P-ANXA1 to the membrane.
Finally, the question remains, what is the biological relevance of the serine phosphorylation of ANXA1? One possibility is that serine phosphorylation is essential for the translocation of the protein across the cell membrane which our recent data suggest is effected via an ATP binding cassette transporter(s) (29) . Alternatively, the inhibitory actions of ANXA1 on the secretion of ACTH and other hormones from the endocrine cells may require serine phosphorylation, a finding that is supported by our recent observation that the biological actions of exogenous ANXA1 in the pituitary are dependent upon PKC (20) and by reports that Ser-P-ANXA1 prevents membrane aggregation (65) . Serine phosphorylation may thus be a significant factor in determining the biological activity of ANXA1 in the pituitary gland as tyrosine phosphorylation has been shown to be in other systems (66) .
